TAMs are activated during 5-FU treatment of CRC to protect CRC cells from 5-FU chemotherapy by secreting cytokines that attenuate JNK-caspase-3 pathway-mediated apoptosis [56]. Here, MAPK8 is linked to colorectal carcinoma.